

Market Scope®

2023 Glaucoma Pharmaceuticals Market Report

Global Analysis for 2022 to 2028

\$4.3B

2023 MARKET
FORECAST

245

COMPREHENSIVE
PAGES

26

COMPETITOR
PROFILES

8

GEOGRAPHIC AND
ECONOMIC BREAKOUTS

What's New

AUTHOR
Peter Downs

PUBLISHED
February 2023

The “2023 Glaucoma Pharmaceuticals Market Report” features new regional sales forecasts, market share analysis of generics and branded drugs by drug class in the United States, new analysis of pipeline products, and a summary of ongoing clinical trials. Also included is an updated analysis of the global and regional prevalence of glaucoma and the latest breakdown of diagnosis and treatment paradigms.

The report also features new survey data from the United States and Europe, including ophthalmologists’ preferences for sustained drug delivery.


Market Scope

2022 Glaucoma Pharmaceuticals Market Report


The “2023 Glaucoma Pharmaceuticals Market Report” analyzes the global and regional markets for glaucoma pharmaceuticals, identifying important trends and key factors for future success. The report provides forecasts through 2028 for branded prostaglandins, generic prostaglandins, beta blockers, carbonic anhydrase inhibitors, alpha agonists, fixed combo drugs, NO-donating compounds, and Rho-kinase inhibitors. The report also extensively discusses pipeline products, covering over 30 drug candidates that are currently under development. Additionally, 26 glaucoma pharmaceutical companies are profiled, discussing their products, strategic market position, background, and outlook. Coverage includes:

- Types of glaucoma and risk factors.
- Diagnosis and treatment of the disease.
- A global view of glaucoma care providers, including ophthalmologists and optometrists.
- Current estimates and five-year forecasts for disease prevalence worldwide.
- Glaucoma medications in the marketplace and their mechanisms of action.
- Discussion of generic versus branded drugs and their market impact.
- The development pipeline for glaucoma pharmaceuticals.
- Profiles of companies making and marketing glaucoma medications.

Glaucoma Pharmaceuticals Revenue Growth by Region



Glaucoma Pharmaceuticals Revenue by Market Competitor



This report provides analysis of current markets for glaucoma medications and forecasts market performance over the next five years. The global market is analyzed based on Market Scope's eight regional/economic categories (the US, Western Europe, Japan, Other Wealthy Nations, China, India, Latin America, and Rest of World), and also uses these categories in global forecasts for disease prevalence. In addition, the report explores data and information on the disease process, glaucoma populations, glaucoma care, and a range of additional topics intended to provide depth and context to the reader's understanding of this ophthalmic segment.

How to Order

Order your "2023 Glaucoma Pharmaceuticals Market Report" now at www.market-scope.com or contact us directly via email or phone.



ENTERPRISE LICENSE

2023 Glaucoma Pharmaceuticals
Market Report

\$11,500

(Price includes a printable PDF and supplemental Excel file with all the tables and figures in the report)



SINGLE-USER LICENSE

2023 Glaucoma Pharmaceuticals
Market Report

\$8,250



Printed Copy

\$250



ONE-YEAR SUBSCRIPTION

Ophthalmic Market
Perspectives Newsletter

\$1,250



Monthly Paper Copies

\$100

314.835.0600 | info@market-scope.com

Our Process

Market Scope's industry reports are meticulously prepared by a dedicated team of in-house analysts with over 100 years of collective ophthalmic market research experience. Each data point is driven by a combination of sources, including:

- Our proprietary global disease population and demographic models
- Analysis of company-published financial reports
- Focused coverage of ophthalmic scientific research, business news, and other activities
- Attendance and participation in worldwide ophthalmic meetings
- Interviews and relationships with company executives and practicing physicians

